Achaogen (AKAO) Stock Price, News & Analysis

Company Overview

Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.11 to $0.11
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 3.34 million shs
• Market Capitalization: $7.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AKAO Stock Analysis - Frequently Asked Questions

How were Achaogen's earnings last quarter?

Achaogen Inc (NASDAQ:AKAO) posted its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative trailing twelve-month return on equity of 357.49% and a negative net margin of 2,136.94%.

What other stocks do shareholders of Achaogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC) and Ciena (CIEN).

Company Calendar

• Last Earnings: 8/06/2018
• Today: 4/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AKAO
• CIK: 1301501
• Web: www.achaogen.com
• Phone: 650-800-3636
• Fax: N/A
• Employees: 206
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-186,510,000.00
• Net Margins: -2,136.94%
• Pretax Margin: N/A
• Return on Equity: -357.49%
• Return on Assets: -127.68%

Debt

• Debt-to-Equity Ratio: 1.00
• Current Ratio: 0.78
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $8.73 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.13) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 63,880,000
• Free Float: N/A
• Market Cap: $7.03 million
• Optionable: Optionable
• Beta: 0.78